WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 4, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, and Anna Berkenblit , Chief Medical Officer, will
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 1, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on January 31, 2022 , the compensation committee of the Company’s Board of Directors granted
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 31, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mimi Huizinga , MD, MPH, FACP has been appointed Senior Vice President and Head of Medical Affairs.
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 3, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2021 the compensation committee of the Company’s Board of Directors granted a
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 29, 2021-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 40th Annual J.P.
Triplet Data Demonstrating Manageable Safety Profile and Promising Anti-Leukemia Activity Highlighted in Oral Presentation Expansion Cohorts in Relapsed and Frontline AML Planned Data for IMGN632 in Three Frontline BPDCN Patients Also Presented in Poster Presentation Showing Clinical Complete
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 6, 2021-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 17,486,364 shares of its common
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 2, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 11,636,364 shares of its common stock at a price of $6.60
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 30, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, $175 million of shares of its
Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4% Median Duration of Response at Data Cutoff is 5.9 Months Continued Demonstration of Favorable Tolerability Profile BLA Submission on Track for First Quarter of 2022 Conference Call to be Held at 8:00 a.m.